Portfolio Company · Operating Co.

Variant Bio

Life Sciences

backed byDCVC

CurrentLife Sciences

Variant Bio

a portfolio company of

DCVC

Status on record: Current

PE Firm Index

Who owns Variant Bio?

Variant Bio is listed as a current portfolio company of DCVC on DCVC's own portfolio page.

Company Snapshot

Variant Bio is a Life Sciences company. Its owner on record, DCVC, is a firm. DCVC lists 443 companies in the index, 58 of them in Life Sciences.

SectorLife Sciences

Parent PE firmDCVC

Ownership statusCurrent

WebsiteNot on record

About the owner

DCVC

Companies in the index: 443

Deep tech venture capital firm backing computational science companies.

Read the DCVC profile

Questions about Variant Bio

Who owns Variant Bio?

Variant Bio is listed as a current portfolio company of DCVC on DCVC's own portfolio page.

What sector is Variant Bio in?

Variant Bio is in Life Sciences. Classified from the owner's portfolio label.

What else does DCVC own in Life Sciences?

DCVC lists 57 other Life Sciences companies in the index, including AbCellera, Aduro Biotech, Alchera Bio, Amide Technologies and AmpliPhi Biosciences.

Sources

DCVC
https://www.dcvc.com/portfolio

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Variant Bio and does not provide investment advice.

Other portfolio companies of DCVC

6 of 442 shown

136 Avenue

13674648 (formerly 1366 Technologies)

See the full DCVC portfolio.

Other Life Sciences companies held by DCVC

AbCellera Aduro Biotech Alchera Bio Amide Technologies AmpliPhi Biosciences Applied BioMath

Other Life Sciences portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

DCVC

Status: Current

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.